Eylea (Aflibercept) (Injection) (Aflibercept)


Indications and Reactions:

Role Indications Reactions
Primary
Age-related Macular Degeneration 83.8%
Macular Degeneration 10.0%
Choroidal Neovascularisation 1.5%
Central Retinal Vein Occlusion 0.8%
Myopia 0.8%
Retinal Detachment 0.8%
Retinal Tear 0.8%
Retinal Vein Occlusion 0.8%
Wet Macular Degeneration 0.8%
Death 41.4%
Visual Acuity Reduced 11.3%
Eye Haemorrhage 6.0%
Vitreous Floaters 6.0%
Vitritis 4.5%
Visual Impairment 3.8%
Myocardial Infarction 3.0%
Non-infectious Endophthalmitis 3.0%
Vitreous Haemorrhage 3.0%
Dementia 2.3%
Retinal Haemorrhage 2.3%
Drug Ineffective 1.5%
Glaucoma 1.5%
Neoplasm Malignant 1.5%
Retinal Disorder 1.5%
Streptococcus Test Positive 1.5%
Sudden Death 1.5%
Vision Blurred 1.5%
Vitrectomy 1.5%
Vitreous Disorder 1.5%
Secondary
Age-related Macular Degeneration 100.0%
Ophthalmic Herpes Simplex 100.0%

Drug Data